Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01092065 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia
A Phase 2 study of Parkinson's Disease, sponsored by Novartis.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 4
- Study locations
NCT01092065 is a Phase 2 study of Parkinson's Disease that has completed, run by Novartis. The registered enrollment target is 23 participants, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT01092065, a Phase 2 study of Parkinson's Disease, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 4
- Study locations
Study Summary
This Phase IIb exploratory study is designed to determine whether AFQ056 is safe and effective and whether it can increase the therapeutic window of L-dopa in patients whose control of their Parkinson's Disease symptoms is limited by the development of dyskinesia induced by use of L-dopa.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AFQ056 with L-dopa
Study Locations (4)
California
- The Parkinsons Institute - Sunnyvale
Colorado
- Colorado Neurological Institute - Englewood
Indiana
- Indiana University School of Medicine - Indianapolis
Kansas
- University of Kansas Medical Center - Parkinson's Disease and Movement Disorders Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01092065
The ClinicalTrials.gov registry entry for NCT01092065 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (96% lower). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01092065 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Colorado, Indiana.
Frequently Asked Questions
What is clinical trial NCT01092065 about?
NCT01092065 is a clinical study titled "Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia". This Phase IIb exploratory study is designed to determine whether AFQ056 is safe and effective and whether it can increase the therapeutic window of L-dopa in patients whose control of their Parkinson's Disease symptoms is limited by the development of dyskinesia induced by use of L-dopa.
What is the current status of trial NCT01092065?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2010-03. Estimated completion is 2011-07.
What conditions does trial NCT01092065 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT01092065?
The interventions under investigation include: Placebo (DRUG), AFQ056 with L-dopa (DRUG).
Who is sponsoring clinical trial NCT01092065?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01092065 being conducted?
This trial has 4 study locations across California, Colorado, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ketamine for Veterans With Parkinson's Disease
RECRUITING · Phase 2
-
Imaging Depression in Parkinson's Disease
RECRUITING · Phase 2
-
Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease
RECRUITING · Phase 2
-
Tenapanor in Synucleinopathy-Related Constipation
RECRUITING · Phase 2
-
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.